Two novel agents work synergistically to treat lung cancer in animal experiment

HOUSTON - Two different agents that have little individual effect on lung cancer when tested in low doses in the lab and in animals have a synergistic impact when combined together, say researchers at The University of Texas M. D. Anderson Cancer. They say this new therapeutic recipe might show potential in disarming the nation's leading cancer killer.

The study, published in the October 20 issue of the Journal of the National Cancer Institute, tested an experimental targeted therapy, the farnesyltransferase inhibitor SCH66336, and an agent, the insulin-like growth factor binding protein-3 (IGFBP-3), and found that even at a combined low dose, tumor size was reduced by half in mice implanted with human lung tumors.

"Together these agents work on multiple pathways important to the survival of a cancer cell, and we look forward to possibly translating our promising findings into a clinical trial," says Ho-Young Lee, Ph.D., an assistant professor in the Department of Thoracic/Head & Neck Medical Oncology Research and lead author of the study.

"Combined, these two agents block two different pathways and appear to have tremendous potential to make an impact in the treatment of lung cancer patients. We are in the process of developing a clinical protocol, which we hope to move forward to patients in the near future," says Waun Ki Hong, M.D., head of the Division of Cancer Medicine and chairman of thoracic/head and neck medical oncology. Scientists from U.S. Food and Drug Administration and from Emory University also participated.

The drugs, when used together, inhibit cancer cell survival pathways in cancer while inducing cell death. IGFBP-3 has demonstrated some effectiveness in laboratory studies involving several different kinds of cancer types, but has not yet been tested in patients. SCH66336 (also known as lonafarnib) already has been tested in an advanced clinical trial treating patients with lung cancer, but results wer

Contact: Laura Sussman
University of Texas M. D. Anderson Cancer Center

Page: 1 2 3

Related medicine news :

1. Diagnosis of prions in patients should utilize novel strategy, team says
2. New math model of heart cell has novel calcium pathway
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. Scientists stalk PPAR-gamma, find novel cancer connection
5. Molecular tailoring of chemotherapy with novel imaging techniques
6. Iris Murdochs last novel reveals first signs of Alzheimers disease
7. Fox Chase Cancer Center researchers identify novel target for detecting ovarian cancer in blood
8. LSUHSC neurosurgical team discovers novel therapy for intractable hiccups
9. Researchers identify novel method of distinguishing Alzheimers disease from other types of dementia
10. Jefferson researchers discover novel gene profile that may identify colon stem cells
11. Combination of toxin and poison may be novel treatment for leukemia

Post Your Comments:

(Date:1/7/2020)... ... January 07, 2020 , ... CBD For The People ... while keeping the focus on the individual customer service experience. Transparency and integrity are ... and the profits second. By taking care of the people first, they know that ...
(Date:1/7/2020)... ... January 07, 2020 , ... Iconic singer, choreographer and actress ... one of the most successful female artists of all time, but also for looking ... Vegas residency and shared in interviews her secrets to making it through 10 hour ...
(Date:1/7/2020)... ... January 06, 2020 , ... MemoryCare.com , ... announced the Best Memory Care Facilities in Lakeland, Florida. The guide identifies 6 ... , According to the Alzheimer’s Association , 5.6 million people age ...
(Date:1/7/2020)... ... 2020 , ... R3 Stem Cell is now offering an ... for hair restoration, facial rejuvenation and sexual wellness. The full course is available ... incredibly popular over the past few years as practitioners are realizing just how ...
(Date:1/7/2020)... Fla. (PRWEB) , ... January 07, 2020 , ... MMJ ... made an award for ?Orphan Drug Designation? for its THC and CBD proprietary drug ... is one of MMJ’s lead drugs and the company is confident that it will ...
Breaking Medicine News(10 mins):
(Date:1/8/2020)... Texas (PRWEB) , ... January ... ... has announced that they are now able to accept Medicare for medication-assisted ... for treatment with methadone, buprenorphine and naltrexone, all FDA-approved medications, as well ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... and telecom service providers, announced today it has been selected by MetLife Stadium ... infrastructure. , “As part of our ongoing commitment to maintain the highest ...
(Date:1/5/2020)... Fla. (PRWEB) , ... January 04, 2020 , ... ... $49 billion worldwide. Device makers and software firms are fighting for leadership in ... Health and Wellbeing 2020 research report, during the past few years, multiple ...
Breaking Medicine Technology:
Cached News: